Adeona Announces Third Quarter 2010 Financial Results and Achievements
ANN ARBOR, Mich., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today its third quarter 2010 financial results as well as recent clinical and operational achievements.
Adeona's Recent Clinical and Operational Achievements:
- All 60 patients are now enrolled in Part 2 of CooperProof-2 clinical study evaluating Zinthionein, a new zinc-based treatment for Alzheimer's disease. In this randomized, double-blind, placebo-controlled study, patients are assessed 3 and 6 months after they begin the once-daily oral treatment or matching placebo. These 60 patients should complete their 6 month treatment by the end of March 2011 and it is anticipated that top-line clinical study results should be available shortly thereafter. If successful, Adeona expects to make its Zinthionein product commercially available as a prescription medical food for patients suffering from Alzheimer's disease and mild cognitive impairment.
- Five peer-reviewed scientific articles have recently been published supporting the role of copper toxicity and zinc deficiency in Alzheimer's disease and mild cognitive decline. These publications were authored by Adeona's scientific founder and consultant, George J. Brewer, M.D., the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.
- 115 of 150 patients have been enrolled in the clinical trial
evaluating Trimesta in women suffering from relapsing-remitting
multiple sclerosis. The randomized, double-blind,